参芪片联合伐昔洛韦治疗复发性生殖器疱疹的研究

目的探讨参芪片联合伐昔洛韦治疗复发性生殖器疱疹的疗效。方法对48例复发性生殖器疱疹患者随机分为治疗组和对照组,治疗组同时口服参芪片与伐昔洛韦3个月,对照组口服伐昔洛韦3个月。观察治疗前后1年期间复发的次数和症状消退时间。结果治疗后对照组与治疗组复发次数有显著性差异,症状消退时间的差异有显著性。结论参芪片联合法昔洛韦可以降低复发性生殖器疱疹的复发次数。     

参芪片联合伐昔洛韦治疗复发陛生殖器疱疹的研究

目的 探讨参芪片联合伐昔洛韦治疗复发性生殖器疱疹的疗效。方法 对48例复发性生殖器疱疹患者随机分为治疗组和对照组，治疗组同日寸口服参芪片与伐昔洛韦3个月，对照组口服伐昔洛韦3个月。观察治疗前后1年期间复发的次数和症状消退日寸间。结果 治疗后对照组与治疗组复发次数有显著性差异，症状消退时间的差异有显著性。结论 参芪片联合法昔洛韦可以降低复发性生殖器疱疹的复发次数。     

伐昔洛韦不同药物使用方案在女性复发性生殖疱疹中的疗效对比及安全性研究

目的:分析伐昔洛韦不同药物使用方案在女性复发性生殖疱疹中的疗效以及安全性,为提高女性复发性生殖疱疹的临床疗效及安全性提供科学依据。方法:选取2014年1月至2015年6月100例复发性生殖器疱疹女性患者,随机分为观察组与对照组,每组50例。所有患者均使用单药伐昔洛韦治疗,采用不同的用药方案。对照组连续用药7d,2次/d,300mg/次;观察组连续用药5d,2次/d,500mg/次。在治疗第1d(D1)、第3d(D3)、第5d(D5)以及第7d(D7),比较两组患者的临床疗效,观察两组治疗前、D1、D3的HSV检出率以及并发症发生率。结果:观察组与对照组在D1、D3、D5、D7的治疗有效率差异无统计学意义(P0.05);观察组与对照组在D1的HSV阳性率显著低于对照组(P0.05),两组在治疗前和D3的HSV阳性率无统计学意义(P0.05);两组治疗过程中的并发症发生率无统计学意义(P0.05)。结论:单次伐昔洛韦用药量增大能够提高复发性生殖器疱疹的临床疗效,能够缩短单纯疱疹病毒在皮损部位的存在时间,并且对用药安全性无任何影响。     

不同剂量和疗程伐昔洛韦治疗带状疱疹的多中心随机双盲对照研究

目的：比较不同剂量和疗程伐昔洛韦治疗带状疱疹的疗效和安全性。方法：选择带状疱疹患者为研究对象，采用多中心、随机、双盲、对照的临床试验。试验组患者采用伐昔洛韦1000mg每日3次口服，共服7d；对照组患者采用伐昔洛韦300mg每日2次口服，共服10d。用药后第3、6和10天观察疗效和不良反应。结果：共入组128例，全分析集（FAS）分析128例，符合方案集（PPS）分析118例。治疗后第3、6和10天，试验组和对照组患者的症状、体征积分下降值及有效率比较差异无统计学意义（P〉0．05）；疼痛视觉模拟评分法（visnal analogue scale，VAS）值比较，两组间差异无统计学意义（P〉0．05），但入组时疼痛VAS值≥8的患者，FAS集分析显示，在治疗后第6、10天VAS值下降两组均存在统计学差异（P〈0．05）；PPS集分析显示治疗后第10天VAS值下降，两组间存在统计学差异俨〈0．05）。试验组和对照组不良反应发生率分别为17．18％和12．50％．主要为嗜睡和恶心。结论：增加伐昔洛韦用量治疗带状疱疹安全、有效，与较低剂量伐昔洛韦组相比，对疼痛程度较严重的患者能更显著地减轻疼痛。     

伐昔洛昔联合甘露聚糖肽治疗复发性生殖器疱疹疗效观察

目的观察伐昔洛韦胶囊联合甘露聚糖肽针剂治疗复发性生殖器疱疹的疗效。方法治疗组45例口服伐昔洛韦胶囊0.3g/次,2次/d;甘露聚糖肽针5mg加利多卡因0.5mL局部皮下注射,3日1次,共10次。对照组40例予口服伐昔洛韦胶囊0.3g/次,2次/d。疗程均为1个月。治疗结束,随访1年。结果治疗组复发率22.2%,低于对照组复发率55.0%,无明显的不良反应。结论伐昔洛韦胶囊联合甘露聚糖肽针治疗生殖器疱疹疗效满意。     

伐昔洛韦不同用药方案治疗复发性生殖器疱疹的疗效观察

目的:探讨分析伐昔洛韦不同用药方案治疗复发性生殖器疱疹的临床疗效。方法:选取我院于2011年2月至2013年4月收治的152例复发性生殖器疱疹的患者,将所有患者按随机数法分为实验组与对照组,两组均为76例。所有患者均服用伐昔洛韦进行治疗,对照组连续服用7d,2次/d,300mg/次,实验组连续服用5d,2次/d,500mg/次。对比分析两组的临床疗效及治疗过程中不良反应的发生情况。结果:实验组与对照组第1d、第3d、第5d、第7d基于积分的有效率的差异比较无统计学意义(P>0.05);实验组治疗第1d HSV培养阳性率要明显低于对照组(P<0.05),两组第2d HSV培养阳性率的差异比较无统计学意义(P>0.05);实验组与对照组治疗过程中不良反应发生率的差异比较无统计学意义(P>0.05)。结论:增加伐昔洛韦的单次用量治疗复发性生殖器疱疹效果显著,单纯疱疹病毒在皮损局部的存在时间明显缩短,且不良反应的发生率未明显提升。     

伐昔洛韦联合胸腺肽肠溶片间歇疗法预防复发性生殖器疱疹疗效观察

目的探讨治疗复发性生殖器疱疹的最佳方法。方法将入选的70例复发性生殖器疱疹患者按就诊顺序随机分成2组,对照组35例,口服伐昔洛韦0.3g,2次/d,连服6d;治疗组35例,口服伐昔洛韦0.3g,2次/d,每月连服6d,胸腺肽肠溶片10mg,3次/d,每月连服14d。两组患者的疗程均为4个月,治疗结束后随访6个月。结果在4个月治疗期间,治疗组复发率(14.72%)明显低于对照组(80.65%);在6个月随访期间,治疗组复发率(52.94%)也明显低于对照组(90.32%),差异均有统计学意义(P均<0.05)。结论伐昔洛韦联合胸腺肽肠溶片间歇疗法治疗复发性生殖器疱疹可有效控制疱疹复发,疗效较好,且治疗方法简单,患者的依从性较好。     

盐酸伐昔洛韦治疗复发性生殖器疱疹的临床疗效观察

目的:观察盐酸伐昔洛韦治疗复发性生殖器疱疹的临床疗效。方法:将我院2011年1月至2013年1月收治的120例复发性生殖器疱疹随机分为观察组与对照组两组,每组60例,观察组患者接受盐酸伐昔洛韦口服治疗,对照组患者接受阿昔洛韦片口服治疗,比较两组患者疗效后疗效以及患者治疗1年后复发率。结果:观察组患者治疗总有效率(91.67%)显著高于对照组(71.67%),(P<0.05)差异有统计学意义;观察组患者治疗1年内复发率(31.67%)显著低于对照组(63.33%),(P<0.05)差异有统计学意义,观察组患者复发面积率以及皮损愈合时间显著低于对照组(P<0.05),两组患者治疗过程中均未出现不良反应。结论:盐酸伐昔洛韦治疗复发性生殖器疱疹的临床疗效显著,能够显著降低复发性生殖器疱疹复发率,且安全性高,值得临床进一步推广应用。     

玉屏风颗粒联合伐昔洛韦治疗复发性生殖器疱疹32例

目的探讨玉屏风颗粒联合伐昔洛韦减少复发性生殖器疱疹发作次数的疗效。方法随机选择64例复发性生殖器疱疹患者,治疗组32例以玉屏风颗粒联合伐昔洛韦治疗;对照组32例单用伐昔洛韦治疗。两组均连续用药6个月,比较两组病例治疗前后1年疱疹的复发次数。结果治疗组复发次数0～7次,平均(1.59±1.29)次;对照组复发次数0～9次,平均(4.28±1.11)次。两组治疗后复发次数比较差异有显著性(P<0.001)。结论玉屏风颗粒联合伐昔洛韦治疗可减少复发性生殖器疱疹的复发和提高治愈率。     

卡介菌多糖核酸联合伐昔洛韦对生殖器疱疹患者Th1/Th2细胞因子的影响

目的:探讨卡介菌多糖核酸联合伐昔洛韦对生殖器疱疹患者Th1/Th2细胞因子的影响。方法:72例复发性生殖器疱疹患者,分为对照组和观察组。对照组使用盐酸伐昔洛韦,观察组采用盐酸伐昔洛韦联合卡介菌多糖核酸治疗。结果:治疗后,观察组患者IL-4水平和IFN-γ水平均优于对照组,差异有统计学意义(P0.01)。治疗后,观察组患者中性粒细胞、Ig G、Ig A、Ig M及C3指标优于对照组,差异有统计学意义(P0.01)。观察组疗效高于对照组,复发率少于对照组,差异有统计学意义(P0.05)。结论:盐酸伐昔洛韦联合卡介菌多糖核酸治疗生殖器疱疹疗效显著,纠正Th1/Th2的失衡,改善患者机体免疫功能,降低患者复发率。     

Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. International Valaciclovir HSV Study Group.

OBJECTIVE: To compare the efficacy and safety of twice daily valaciclovir with five times daily aciclovir in the treatment of an episode of recurrent genital herpes simplex virus (HSV) infection in immunocompetent individuals. METHODS: 739 patients with a history of recurrent genital HSV infection received either oral valaciclovir (500 mg twice daily) or aciclovir (200 mg five times daily) for 5-days for treatment of their next recurrent episode in a controlled, randomised, double blind trial. Patients self initiated therapy at the first signs and/or symptoms of the HSV recurrence, then were assessed in clinic on five occasions over 7 days, and twice weekly thereafter until lesions had healed. Safety was evaluated through adverse experience reports and haematology and biochemistry monitoring. RESULTS: No significant differences were detected between valaciclovir and aciclovir for the primary endpoint, the duration of all signs and symptoms which included lesion healing and pain/discomfort. The hazard ratio [95% confidence interval] for valaciclovir v aciclovir was 0.93 [0.79, 1.08]. Lesion healing time was similar in each treatment group (hazard ratio valaciclovir v aciclovir 0.96 [0.80, 1.14]). The odds ratio of valaciclovir v aciclovir in preventing the development of vesicular/ulcerative lesions was 1.08 [0.82, 1.42]. Percentages of patients in whom all HSV cultures were negative were similar in the valaciclovir and aciclovir groups at 59% and 54% respectively; for patients having equal to or more than one positive culture result after treatment initiation, cessation of virus shedding was similarly rapid for the two treatments (hazard ratio 0.98 [0.75, 1.27]). The safety profiles of valaciclovir and aciclovir were comparable with adverse experiences being infrequent and generally mild. CONCLUSION: This study has demonstrated that valaciclovir 500 mg twice daily is equivalent in efficacy to aciclovir 200 mg five times daily as episodic treatment of recurrent genital HSV infection. Valaciclovir maintains the established efficacy and safety of aciclovir but offers a much more convenient twice daily dosing regimen.     

Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. International Valaciclovir HSV Study Group.

OBJECTIVE: To determine the efficacy and safety of once daily valaciclovir for the suppression of recurrent genital herpes simplex virus (HSV) infection in immunocompetent patients. METHODS: 382 otherwise healthy patients with a history of frequently recurring genital HSV infection (eight recurrences per year) were randomly allocated to receive either oral valaciclovir (500 mg once daily) or placebo (3:1 ratio) for 16 weeks or until the first genital HSV recurrence, whichever occurred first. Patients were clinically assessed at regular intervals and also if they experienced a recurrence. Safety was evaluated through adverse experience reporting and monitoring of haematology and biochemistry variables. On completion of the double blind phase, patients were eligible for follow up to a maximum of 48 weeks' treatment with open label valaciclovir (500 mg once daily) for further safety monitoring. The results from the double blind phase of the study are reported here. RESULTS: A significant difference was detected between valaciclovir and placebo in the time to first recurrence of genital HSV infection. The hazard ratio [95% confidence interval] for valaciclovir v placebo was 0.155 [0.112, 0.214], p < 0.0001. Valaciclovir prevented or delayed 85% of the recurrences that would have occurred with placebo. After 16 weeks (day 112) with treatment, 69% of patients receiving valaciclovir were recurrence free compared with only 9.5% of patients assigned to placebo. The safety profiles of valaciclovir and placebo were comparable, with adverse experiences being infrequent and generally mild. CONCLUSION: This study has demonstrated that once daily valaciclovir (500 mg), is highly effective and well tolerated for the suppression of recurrent genital HSV infection. Once daily dosing with valaciclovir provides a more convenient dosing regimen than the more frequent aciclovir regimens.     

Aborted genital herpes simplex virus lesions: findings from a randomised controlled trial with valaciclovir

OBJECTIVES: In prospective trials, episodic valaciclovir significantly increased the chance of preventing or aborting the development of painful vesicular genital herpes simplex virus (HSV) lesions compared with placebo. We explored the clinical outcome of aborted lesions and its association with early treatment in a study designed to compare 3 and 5 days' treatment with valaciclovir. METHODS: In a randomised controlled trial, valaciclovir 500 mg twice daily for 3 or 5 days was initiated at the first symptoms of a genital herpes outbreak. The primary end point was length of episode with pain, HSV shedding, and aborted lesions secondary end points. The effect of time from symptom recognition to treatment initiation on aborted lesions was assessed in a post hoc analysis. RESULTS: In 531 patients, no differences were observed between 3 and 5 days' treatment in episode duration (median 4.7 v 4.6 days), loss of pain/discomfort (2.8 v 3.0 days), or lesion healing (4.9 v 4.5 days). Vesicular lesions were aborted in 27% of patients treated for 3 days v 21% of patients receiving valaciclovir for 5 days. The odds of achieving an aborted episode were 1.93 (95% CI: 1.28 to 2.90) times higher for those initiating treatment with valaciclovir within 6 hours of first sign or symptom. CONCLUSIONS: There was no difference between 3 and 5 days' treatment in reducing episode duration or lesion abortion. Prompt treatment with valaciclovir can abort genital HSV reactivation episodes, preventing a vesicular outbreak. Maximum treatment benefit depends on prompt therapy after recognition of symptoms.     

伐昔洛韦抑制疗法和间歇疗法预防生殖器疱疹复发作用比较

目的　比较伐昔洛韦每日抑制疗法和间歇疗法对预防生殖器疱疹复发的作用。方法　 65例复发性生殖器疱疹患者按不同复发频度分层后以半随机方式分配至间歇疗法组 (A组 )和每日抑制疗法组 (B组 )。A组 3 4例 ,当疱疹复发时口服伐昔洛韦 3 0 0mg ,2次 /d ,连服 6天 ;B组 3 1例 ,口服伐昔洛韦 3 0 0mg ,1次 /d ,连服 4个月。治疗后观察随访 6个月。结果　在 4个月治疗期间以及其后 6个月随访期间 ,B组每半年平均复发次数均显著低于A组 (P均 <0 .0 0 1)。结论　伐昔洛韦每日抑制疗法对预防和延迟生殖器疱疹复发具有显著作用 ,疗效明显优于间歇疗法。     

万乃洛韦结合膦甲酸钠注射液治疗复发性生殖器疱疹的临床效果观察

目的：研究万乃洛韦结合膦甲酸钠注射液治疗复发性生殖器疱疹的临床效果。方法：本组抽取我院于2011年4月至2013年4月收治的复发性生殖器疱疹患者58例,将患者随机均分为两组,观察组患者采用万乃洛韦结合膦甲酸钠注射液治疗,对照组患者采用阿昔洛韦治疗,观察两组患者的临床疗效以及病情复发情况。结果：观察组患者的治疗有效率和1年内病情未复发率分别为100％、62．07％;对照组组患者的治疗有效率和1年内病情未复发率分别为79．31％、24．14％,差异具有统计学意义（P〈0．05）。结论：复发性生殖器疱疹患者入院后,取万乃洛韦结合膦甲酸钠注射液治疗,能够降低疾病的复发率,值得推广使用。     

三种方法预防复发性生殖器疱疹疗效观察

目的探讨治疗复发性生殖器疱疹的有效方法。方法 A组42例,伐昔洛韦0.3g,1次/d;B组41例,阿昔洛韦0.4g,2次/d;C组37例,阿昔洛韦0.4g,转移因子6mg,2次/d,疗程均为6个月。结果各组复发率分别为23.80%,29.30%,18.90%,各组间差异无统计学意义。结论采用6个月抑制疗法治疗生殖器疱疹,可有效控制复发。     

Valaciclovir as a single dose during prodrome of herpes facialis: a pilot randomized double-blind clinical trial

BACKGROUND: Randomized clinical trials of valaciclovir in recurrent herpes labialis are lacking. OBJECTIVES: To determine whether a single course of valaciclovir, i.e. 500, 1000 or 2000 mg, administered during the prodrome of herpes facialis, could be beneficial. METHODS: Three hundred and forty-five out-patients with herpes labialis were screened and randomized for a multicentre, double-blind clinical trial. Ninety-six patients had no recurrence after 6 months of follow-up; 249 patients were finally included in the intent-to-treat (ITT) population. The main outcome measure was the rate of aborted episodes at day 3. The three treatment groups were similar at baseline. RESULTS: There was no statistically significant difference between the groups in rates of aborted lesions at day 3 in the ITT population, in particular between the 500 mg and 2000 mg treatment groups. CONCLUSIONS: Although a placebo group was not included in this pilot study, a single dose of valaciclovir was not considered beneficial in patients with recurrent herpes facialis.